Phaseline

Targets › SMN1

SMN1: drug programs, companies and trials

8 programs from 6 companies in 11 trials: 7 Phase 1, 3 Phase 3, 1 Phase 4; Neurology, Other; next expected readout Dec 2026.

Open in Phaseline: the race on SMN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisOnasemnogene Abeparvovec-brve (ITVISMA®)
Adeno-associated virus serotype 9 (AAV9) delivering SMN1 gene
SMN1Phase 4Spinal Muscular AtrophyMay 2032
GeneCradleGC101
Self-complementary AAV9 delivering codon-optimized SMN coding sequence
SMN1Phase 3SMA - Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy; SMA IIDec 2026
Novartisonasemnogene abeparvovec
Survival motor neuron protein exogenous gene
SMN2, SMN1Phase 3Spinal Muscular Atrophy (SMA)Apr 2031
NovartisOnasemnogene Abeparvovec
Survival motor neuron protein exogenous gene
SMN2, SMN1Phase 3Spinal Muscular Atrophy Type IDec 2035
Lantu Biopharmavesemnogene lantuparvovec
AAV-mediated SMN1 gene delivery
SMN1Phase 1Spinal Muscular AtrophyOct 2027
Gemma BiotherapeuticsGB221
Gene therapy delivering functional SMN1 gene via AAV vector to motor neurons
SMN1Phase 1Spinal Muscular Atrophy Type IDec 2028
Lanyue Biotech (Hangzhou)SKG0201 Injection
rAAV vector-based gene therapy delivering SMN1 gene
SMN1Phase 1Spinal Muscular Atrophy 1May 2029
BiocadANB-004
Adeno-associated viral vector carrying the SMN gene
SMN1Phase 1Spinal Muscular Atrophy (SMA)Aug 2030

Conditions

Spinal Muscular Atrophy (3) Spinal Muscular Atrophy Type I (2) Spinal Muscular Atrophy (SMA) (2) SMA - Spinal Muscular Atrophy (1) Spinal Muscular Atrophy Type 3 (1) SMA II (1) Spinal Muscular Atrophy 1 (1)

Modalities

other (7), protein or peptide (1)

Companies

Novartis (3) Gemma Biotherapeutics (1) GeneCradle (1) Lanyue Biotech (Hangzhou) (1) Biocad (1) Lantu Biopharma (1)

Related targets

SMN2 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.